NASDAQ:ADAP
Adaptimmune Therapeutics plc Stock News
$1.58
+0 (+0%)
At Close: Mar 28, 2024
Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
08:00am, Thursday, 21'st Oct 2021
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and
2 Top Healthcare Stocks That Could Be Bought Out in 2022
07:00am, Saturday, 16'th Oct 2021
These two novel-drug makers could be top takeover targets next year.
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
08:00am, Tuesday, 05'th Oct 2021
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -
Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
10:18am, Wednesday, 29'th Sep 2021
Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.
Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions?
09:59am, Friday, 24'th Sep 2021
Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Why Adaptimmune Therapeutics Was Sinking This Week
04:48pm, Friday, 17'th Sep 2021
Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.
Adaptimmune Shares Encouraging Data From Solid Tumor Trial
09:50am, Monday, 13'th Sep 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therap
ADAP Stock: Why It Increased Today
08:02am, Monday, 13'th Sep 2021
The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased by over 10% pre-market today. This is why it happened.
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -
Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies
12:30pm, Wednesday, 08'th Sep 2021
Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.
ADAP Stock: 28.95% Increase Explanation
04:19pm, Tuesday, 07'th Sep 2021
The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased 28.95% today. This is why it happened.
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
10:16am, Tuesday, 07'th Sep 2021
A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
09:08am, Tuesday, 07'th Sep 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY), to develop and commercialize allogeneic
- Combining both companies' cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and
Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate
12:17pm, Monday, 06'th Sep 2021
Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.